Your browser doesn't support javascript.
loading
A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
Fermini, Bernard; Hancox, Jules C; Abi-Gerges, Najah; Bridgland-Taylor, Matthew; Chaudhary, Khuram W; Colatsky, Thomas; Correll, Krystle; Crumb, William; Damiano, Bruce; Erdemli, Gul; Gintant, Gary; Imredy, John; Koerner, John; Kramer, James; Levesque, Paul; Li, Zhihua; Lindqvist, Anders; Obejero-Paz, Carlos A; Rampe, David; Sawada, Kohei; Strauss, David G; Vandenberg, Jamie I.
Affiliation
  • Fermini B; Global Safety Pharmacology, Pfizer Inc., Groton, CT, USA Bernard.fermini@pfizer.com.
  • Hancox JC; School of Physiology and Pharmacology, University of Bristol, Bristol, UK.
  • Abi-Gerges N; Translational Safety, Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca R&D, Macclesfield, UK AnaBios Corporation, San Diego, CA, USA.
  • Bridgland-Taylor M; Discovery Sciences, Innovative Medicines and Early Development, AstraZeneca R&D, Macclesfield, UK.
  • Chaudhary KW; Safety Assessment, GlaxoSmithKline, King of Prussia, PA, USA.
  • Colatsky T; Division of Applied Regulatory Science, CDER, US Food and Drug Administration, Silver Spring, MD, USA.
  • Correll K; Safety Pharmacology Society, Reston, VA, USA.
  • Crumb W; Zenas Technologies LLC, New Orleans, LA, USA.
  • Damiano B; Global Safety Pharmacology, Discovery Sciences, Janssen Research & Development LLC, Spring House, PA, USA.
  • Erdemli G; Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Inc, Cambridge, MA, USA.
  • Gintant G; Department of Integrative Pharmacology, Integrated Sciences & Technology, AbbVie, North Chicago, IL, USA.
  • Imredy J; Department of Safety Assessment, Merck & Co, Kenilworth, NJ, USA.
  • Koerner J; Division of Cardiovascular and Renal Products, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Kramer J; ChanTest, A Charles River Company, Cleveland, OH, USA.
  • Levesque P; Bristol Myers Squibb Research & Development, Princeton, NJ, USA.
  • Li Z; Division of Applied Regulatory Science, CDER, US Food and Drug Administration, Silver Spring, MD, USA.
  • Lindqvist A; Biolin Scientific, Ballerup, DK.
  • Obejero-Paz CA; ChanTest, A Charles River Company, Cleveland, OH, USA.
  • Rampe D; Preclinical Safety, Sanofi, Bridgewater, NJ, USA.
  • Sawada K; Global Cardiovascular Assessment, Eisai Co., Ltd., Ibaraki, Japan.
  • Strauss DG; Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Vandenberg JI; Victor Chang Cardiac Research Institute, St Vincent's Clinical School, University of NSW, Darlinghurst, NSW, Australia.
J Biomol Screen ; 21(1): 1-11, 2016 Jan.
Article in En | MEDLINE | ID: mdl-26170255
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arrhythmias, Cardiac / Drug-Related Side Effects and Adverse Reactions / Heart Type of study: Diagnostic_studies / Guideline Limits: Animals / Humans Language: En Journal: J Biomol Screen Journal subject: BIOLOGIA MOLECULAR Year: 2016 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arrhythmias, Cardiac / Drug-Related Side Effects and Adverse Reactions / Heart Type of study: Diagnostic_studies / Guideline Limits: Animals / Humans Language: En Journal: J Biomol Screen Journal subject: BIOLOGIA MOLECULAR Year: 2016 Type: Article Affiliation country: United States